SI20814A - Priprava amorfnega atorvastatina - Google Patents

Priprava amorfnega atorvastatina Download PDF

Info

Publication number
SI20814A
SI20814A SI200100010A SI200100010A SI20814A SI 20814 A SI20814 A SI 20814A SI 200100010 A SI200100010 A SI 200100010A SI 200100010 A SI200100010 A SI 200100010A SI 20814 A SI20814 A SI 20814A
Authority
SI
Slovenia
Prior art keywords
atorvastatin
solution
temperature
water
amorphous
Prior art date
Application number
SI200100010A
Other languages
English (en)
Slovenian (sl)
Inventor
Gorazd Sor�ak
Original Assignee
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority to SI200100010A priority Critical patent/SI20814A/sl
Priority to HU0302797A priority patent/HU227535B1/hu
Priority to DK02734878T priority patent/DK1373202T3/da
Priority to JP2002559389A priority patent/JP4336106B2/ja
Priority to EEP200300333A priority patent/EE05270B1/xx
Priority to EP02734878A priority patent/EP1373202B1/de
Priority to CNB028039688A priority patent/CN1260213C/zh
Priority to RU2003124962/04A priority patent/RU2324679C2/ru
Priority to IL15706802A priority patent/IL157068A0/xx
Priority to ES02734878T priority patent/ES2240748T3/es
Priority to CA002435954A priority patent/CA2435954C/en
Priority to SI200230156T priority patent/SI1373202T1/sl
Priority to CZ20031988A priority patent/CZ20031988A3/cs
Priority to AT02734878T priority patent/ATE294159T1/de
Priority to UA2003076436A priority patent/UA73829C2/uk
Priority to PCT/IB2002/000161 priority patent/WO2002059087A1/en
Priority to DE60203894T priority patent/DE60203894T2/de
Priority to BR0206637-8A priority patent/BR0206637A/pt
Priority to AU2002219455A priority patent/AU2002219455B2/en
Priority to YUP-568/03A priority patent/RS51010B/sr
Priority to PL361763A priority patent/PL209428B1/pl
Priority to KR1020037009509A priority patent/KR100882066B1/ko
Priority to SK908-2003A priority patent/SK286593B6/sk
Priority to MXPA03006548A priority patent/MXPA03006548A/es
Publication of SI20814A publication Critical patent/SI20814A/sl
Priority to US10/323,444 priority patent/US6750353B2/en
Priority to ZA200305307A priority patent/ZA200305307B/xx
Priority to HR20030575A priority patent/HRP20030575B1/xx
Priority to BG108017A priority patent/BG108017A/bg
Priority to IL157068A priority patent/IL157068A/en
Priority to US10/677,344 priority patent/US7074940B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200100010A 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina SI20814A (sl)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium
DE60203894T DE60203894T2 (de) 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium
DK02734878T DK1373202T3 (da) 2001-01-23 2002-01-22 Fremstilling af ikke-krystallinsk atorvastatincalcium
EEP200300333A EE05270B1 (et) 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod
EP02734878A EP1373202B1 (de) 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium
CNB028039688A CN1260213C (zh) 2001-01-23 2002-01-22 非结晶阿托伐他汀钙的制备
RU2003124962/04A RU2324679C2 (ru) 2001-01-23 2002-01-22 Получение некристаллического аторвастатина кальция
IL15706802A IL157068A0 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium
ES02734878T ES2240748T3 (es) 2001-01-23 2002-01-22 Preparacion de atorvastatina de calcio no cristalina.
CA002435954A CA2435954C (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium
SI200230156T SI1373202T1 (sl) 2001-01-23 2002-01-22 Priprava nekristalnega atorvastatin kalcija
CZ20031988A CZ20031988A3 (cs) 2001-01-23 2002-01-22 Způsob přípravy nekrystalické vápenaté soli atorvastatinu
AT02734878T ATE294159T1 (de) 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium
UA2003076436A UA73829C2 (en) 2001-01-23 2002-01-22 A method for the preparation of non-crystalline atorvastatin calcium and pharmaceutical composition
HU0302797A HU227535B1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium
JP2002559389A JP4336106B2 (ja) 2001-01-23 2002-01-22 非晶質アトルバスタチンカルシウムの調製
BR0206637-8A BR0206637A (pt) 2001-01-23 2002-01-22 Processo para preparação de atorvastatina em forma não cristalina e de formulação farmacêutica
AU2002219455A AU2002219455B2 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium
YUP-568/03A RS51010B (sr) 2001-01-23 2002-01-22 Pripremanje nekristalinskog atorvastatin-kalcijuma
PL361763A PL209428B1 (pl) 2001-01-23 2002-01-22 Sposób wytwarzania soli wapniowej atorwastatyny w postaci niekrystalicznej oraz sposób wytwarzania preparatu farmaceutycznego zawierającego sól wapniową atorwastatyny w postaci niekrystalicznej
KR1020037009509A KR100882066B1 (ko) 2001-01-23 2002-01-22 비결정 아토르바스타틴 칼슘의 제조방법
SK908-2003A SK286593B6 (sk) 2001-01-23 2002-01-22 Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu
MXPA03006548A MXPA03006548A (es) 2001-01-23 2002-01-22 Preparacion de atorvastatin de calcio no cristalino.
US10/323,444 US6750353B2 (en) 2001-01-23 2002-12-18 Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline form
ZA200305307A ZA200305307B (en) 2001-01-23 2003-07-09 Preparation of non-crystalline at atorvastatin calcium.
HR20030575A HRP20030575B1 (en) 2001-01-23 2003-07-15 Preparation of non-crystalline atorvastatin calcium
BG108017A BG108017A (bg) 2001-01-23 2003-07-22 Пол"-аван... на н...кри''ал...н кал-и...в а'орва''а'ин
IL157068A IL157068A (en) 2001-01-23 2003-07-23 Preparation of non-crystalline atorvastatin calcium
US10/677,344 US7074940B2 (en) 2001-01-23 2003-10-03 Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina

Publications (1)

Publication Number Publication Date
SI20814A true SI20814A (sl) 2002-08-31

Family

ID=20432812

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
SI200230156T SI1373202T1 (sl) 2001-01-23 2002-01-22 Priprava nekristalnega atorvastatin kalcija

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200230156T SI1373202T1 (sl) 2001-01-23 2002-01-22 Priprava nekristalnega atorvastatin kalcija

Country Status (27)

Country Link
US (2) US6750353B2 (de)
EP (1) EP1373202B1 (de)
JP (1) JP4336106B2 (de)
KR (1) KR100882066B1 (de)
CN (1) CN1260213C (de)
AT (1) ATE294159T1 (de)
AU (1) AU2002219455B2 (de)
BG (1) BG108017A (de)
BR (1) BR0206637A (de)
CA (1) CA2435954C (de)
CZ (1) CZ20031988A3 (de)
DE (1) DE60203894T2 (de)
DK (1) DK1373202T3 (de)
EE (1) EE05270B1 (de)
ES (1) ES2240748T3 (de)
HR (1) HRP20030575B1 (de)
HU (1) HU227535B1 (de)
IL (2) IL157068A0 (de)
MX (1) MXPA03006548A (de)
PL (1) PL209428B1 (de)
RS (1) RS51010B (de)
RU (1) RU2324679C2 (de)
SI (2) SI20814A (de)
SK (1) SK286593B6 (de)
UA (1) UA73829C2 (de)
WO (1) WO2002059087A1 (de)
ZA (1) ZA200305307B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
EP1365995A2 (de) * 2001-02-27 2003-12-03 Council of Scientific and Industrial Research Ätherisches öl enthaltende zusammensetzungen für trinkwasserentkeimung
EA005317B1 (ru) 2001-06-29 2004-12-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
MXPA04007995A (es) 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2530446A1 (en) 2003-07-02 2005-01-13 Egis Gyogyszergyar Rt. Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
AU2003272082A1 (en) * 2003-10-07 2005-04-21 Biocon Limited Process for the production of atorvastatin calcium
CA2551549A1 (en) * 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
EP1577297A1 (de) 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Verfahren zur Herstellung von amorphem Atorvastatin Kalzium
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
JP2008510798A (ja) * 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
EP1979313A1 (de) * 2006-01-31 2008-10-15 Jubilant Organosys Limited Verfahren zur herstellung von amorphem atorvastatin-calciumsalz
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
BRPI0818575A2 (pt) * 2007-10-17 2014-10-07 Todd F Ovokaitys Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2011131605A1 (en) * 2010-04-19 2011-10-27 Dsm Ip Assets B.V. Production of atorvastatin low in ether impurities
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128862A (en) * 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
PL361763A1 (en) 2004-10-04
ES2240748T3 (es) 2005-10-16
JP2005503997A (ja) 2005-02-10
CA2435954A1 (en) 2002-08-01
JP4336106B2 (ja) 2009-09-30
US20040072895A1 (en) 2004-04-15
KR20030077003A (ko) 2003-09-29
SK286593B6 (sk) 2009-01-07
DE60203894T2 (de) 2006-01-19
YU56803A (sh) 2006-05-25
DK1373202T3 (da) 2005-05-17
SI1373202T1 (sl) 2005-12-31
HUP0302797A2 (hu) 2003-11-28
US7074940B2 (en) 2006-07-11
ATE294159T1 (de) 2005-05-15
IL157068A0 (en) 2004-02-08
BR0206637A (pt) 2004-08-03
US20030109569A1 (en) 2003-06-12
DE60203894D1 (de) 2005-06-02
IL157068A (en) 2009-09-01
AU2002219455B2 (en) 2007-04-26
HRP20030575B1 (en) 2011-10-31
RU2003124962A (ru) 2005-01-10
CN1260213C (zh) 2006-06-21
BG108017A (bg) 2004-08-31
CA2435954C (en) 2008-06-03
HUP0302797A3 (en) 2009-09-28
HU227535B1 (en) 2011-08-29
CZ20031988A3 (cs) 2003-11-12
UA73829C2 (en) 2005-09-15
MXPA03006548A (es) 2004-10-15
KR100882066B1 (ko) 2009-02-10
US6750353B2 (en) 2004-06-15
EP1373202A1 (de) 2004-01-02
EE05270B1 (et) 2010-02-15
RS51010B (sr) 2010-10-31
SK9082003A3 (en) 2003-12-02
HRP20030575A2 (en) 2005-06-30
ZA200305307B (en) 2004-07-09
WO2002059087A1 (en) 2002-08-01
EP1373202B1 (de) 2005-04-27
RU2324679C2 (ru) 2008-05-20
CN1487921A (zh) 2004-04-07
EE200300333A (et) 2003-10-15
PL209428B1 (pl) 2011-08-31

Similar Documents

Publication Publication Date Title
SI20814A (sl) Priprava amorfnega atorvastatina
SI20425A (sl) Priprava amorfnega atorvastatina
EP1341785B1 (de) Hydrolyse von [r(r*,r*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-heptansäureestern mit calciumhydroxid
EP1566376A1 (de) Herstellung von Amiden Aminosäuren
KR20030016220A (ko) 항균제의 질산염들
JP2005503997A5 (de)
CN112661584B (zh) 一种光催化n-烷基酰胺化合物的制备方法
BRPI0608219A2 (pt) processo para preparar um grupo de amidina protegido, e, uso de um agente de ativação de tio-ceto
CN101965334A (zh) 新的前体
WO1992021656A1 (en) Water-soluble biologically active ammonium salts
JPH07116116B2 (ja) ３−アミノアクリル酸エステルの製造法
HU229260B1 (en) Process for preparation of rosuvastatin salts
US20020086994A1 (en) Deprotection processes
WO2005005384A1 (en) Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
KR100833439B1 (ko) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
JP2006219498A (ja) ２−アミノメチル−４−シアノ−チアゾールの製法
CN106588755A (zh) 一种制备抗艾滋病药物阿扎那韦单体的方法
JPS6130576A (ja) ２−アミノ−５−シアノピリミジンの製法
US20070083054A1 (en) Novel amides of lipoic acid
CA2268775C (en) Process for the preparation of phtalide
JP3395594B2 (ja) ２−ピペラジンカルボン酸塩の製造方法
CN104059087A (zh) 一种阿扑西林的合成方法
Tretyakov et al. 2-Cyano-4, 4, 5, 5-tetramethyl-4, 5-dihydro-1$ H $-imidazol-1-oxyl-3-oxide as key compound for preparation of nitronyl and imino nitroxides
CN103936666B (zh) 一种2,4-哌啶二酮的合成方法
CN115572747A (zh) 托匹司他的制备方法

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20101001